Allogeneic haematopoietic cell transplantation (alloHCT) is a complex procedure that involves many different factors: patient characteristics, disease characteristics, donor choice, stem cell source, choice of conditioning regimen, graft versus host disease (GvHD) prevention and treatment, prevention and treatment of disease relapse and management of (non-)infectious complications. This paper discusses some key studies that were presented regarding patient characteristics, donor choice, GvHD prophylaxis and treatment and treatment of disease relapse after alloHCT. Now two years into the pandemic, it is impossible to ignore SARS-CoV-2, seroconversion after mRNA vaccination of alloHCT recipients in France will be discussed.

(BELG J HEMATOL 2022;13(1):43-7)